Cargando…
Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals
Both obesity and chronic inflammation are often associated with insulin resistance and type 2 diabetes. The Zucker diabetic fatty (ZDF) rat (fa/fa) is an obese animal model frequently used in type 2 diabetes research. The current study determines whether chronic administration (from 5 weeks of age t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234283/ https://www.ncbi.nlm.nih.gov/pubmed/25419150 http://dx.doi.org/10.2147/DMSO.S69891 |
_version_ | 1782344828085862400 |
---|---|
author | Wang, Xi DuBois, Debra C Sukumaran, Siddharth Ayyar, Vivaswath Jusko, William J Almon, Richard R |
author_facet | Wang, Xi DuBois, Debra C Sukumaran, Siddharth Ayyar, Vivaswath Jusko, William J Almon, Richard R |
author_sort | Wang, Xi |
collection | PubMed |
description | Both obesity and chronic inflammation are often associated with insulin resistance and type 2 diabetes. The Zucker diabetic fatty (ZDF) rat (fa/fa) is an obese animal model frequently used in type 2 diabetes research. The current study determines whether chronic administration (from 5 weeks of age through 24 weeks of age) of salsalate, a salicylate with anti-inflammatory properties, would be effective in mitigating diabetes disease progression in ZDF rats. Although a trend existed for lower blood glucose in the salsalate-treated group, significant differences were obscured by high animal-level variability. However, even in the non-drug-treated group, not all ZDF rats became diabetic as expected. Therefore, animals were parsed into two groups, regardless of drug treatment: normoglycemic ZDF rats, which maintained blood glucose profiles identical to nondiabetic Zucker lean rats (ZLRs), and hyperglycemic ZDF rats, which exhibited progressive elevation in blood glucose. To ascertain the differences between ZDF rats that became hyperglycemic and those that did not, relevant physiological indices and expression levels of adiponectin, tumor necrosis factor-α, interleukin-6, and glucocorticoid-induced leucine zipper messenger RNAs in adipose tissue were measured at sacrifice. Plasma C-reactive protein concentrations and expression levels of cytokine and glucocorticoid-induced leucine zipper messenger RNAs suggested more prevalent chronic inflammation in hyperglycemic animals. Early elevation of the insulin-sensitizing adipokine, adiponectin, was present in both ZDF groups, with the rate of its age-related decline faster in hyperglycemic animals. The most marked difference between the two groups of ZDF animals was in insulin output. Although the two ZDF populations had very similar elevated plasma insulin concentrations for the first 10 weeks, after that time, plasma insulin decreased markedly in the animals that became hyperglycemic, whereas it remained high in the normoglycemic ZDF rats. Thus, hyperglycemic ZDF animals exhibit both insulin resistance and progressive beta cell failure, whereas normoglycemic ZDF rats exhibit a lesser degree of insulin resistance that does not progress to beta cell failure. In these respects, the normoglycemic ZDF rats appear to revert back to a phenotype that strongly resembles that of nondiabetic Zucker fatty rats from which they were derived. |
format | Online Article Text |
id | pubmed-4234283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42342832014-11-21 Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals Wang, Xi DuBois, Debra C Sukumaran, Siddharth Ayyar, Vivaswath Jusko, William J Almon, Richard R Diabetes Metab Syndr Obes Original Research Both obesity and chronic inflammation are often associated with insulin resistance and type 2 diabetes. The Zucker diabetic fatty (ZDF) rat (fa/fa) is an obese animal model frequently used in type 2 diabetes research. The current study determines whether chronic administration (from 5 weeks of age through 24 weeks of age) of salsalate, a salicylate with anti-inflammatory properties, would be effective in mitigating diabetes disease progression in ZDF rats. Although a trend existed for lower blood glucose in the salsalate-treated group, significant differences were obscured by high animal-level variability. However, even in the non-drug-treated group, not all ZDF rats became diabetic as expected. Therefore, animals were parsed into two groups, regardless of drug treatment: normoglycemic ZDF rats, which maintained blood glucose profiles identical to nondiabetic Zucker lean rats (ZLRs), and hyperglycemic ZDF rats, which exhibited progressive elevation in blood glucose. To ascertain the differences between ZDF rats that became hyperglycemic and those that did not, relevant physiological indices and expression levels of adiponectin, tumor necrosis factor-α, interleukin-6, and glucocorticoid-induced leucine zipper messenger RNAs in adipose tissue were measured at sacrifice. Plasma C-reactive protein concentrations and expression levels of cytokine and glucocorticoid-induced leucine zipper messenger RNAs suggested more prevalent chronic inflammation in hyperglycemic animals. Early elevation of the insulin-sensitizing adipokine, adiponectin, was present in both ZDF groups, with the rate of its age-related decline faster in hyperglycemic animals. The most marked difference between the two groups of ZDF animals was in insulin output. Although the two ZDF populations had very similar elevated plasma insulin concentrations for the first 10 weeks, after that time, plasma insulin decreased markedly in the animals that became hyperglycemic, whereas it remained high in the normoglycemic ZDF rats. Thus, hyperglycemic ZDF animals exhibit both insulin resistance and progressive beta cell failure, whereas normoglycemic ZDF rats exhibit a lesser degree of insulin resistance that does not progress to beta cell failure. In these respects, the normoglycemic ZDF rats appear to revert back to a phenotype that strongly resembles that of nondiabetic Zucker fatty rats from which they were derived. Dove Medical Press 2014-11-11 /pmc/articles/PMC4234283/ /pubmed/25419150 http://dx.doi.org/10.2147/DMSO.S69891 Text en © 2014 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wang, Xi DuBois, Debra C Sukumaran, Siddharth Ayyar, Vivaswath Jusko, William J Almon, Richard R Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
title | Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
title_full | Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
title_fullStr | Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
title_full_unstemmed | Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
title_short | Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
title_sort | variability in zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234283/ https://www.ncbi.nlm.nih.gov/pubmed/25419150 http://dx.doi.org/10.2147/DMSO.S69891 |
work_keys_str_mv | AT wangxi variabilityinzuckerdiabeticfattyratsdifferencesindiseaseprogressioninhyperglycemicandnormoglycemicanimals AT duboisdebrac variabilityinzuckerdiabeticfattyratsdifferencesindiseaseprogressioninhyperglycemicandnormoglycemicanimals AT sukumaransiddharth variabilityinzuckerdiabeticfattyratsdifferencesindiseaseprogressioninhyperglycemicandnormoglycemicanimals AT ayyarvivaswath variabilityinzuckerdiabeticfattyratsdifferencesindiseaseprogressioninhyperglycemicandnormoglycemicanimals AT juskowilliamj variabilityinzuckerdiabeticfattyratsdifferencesindiseaseprogressioninhyperglycemicandnormoglycemicanimals AT almonrichardr variabilityinzuckerdiabeticfattyratsdifferencesindiseaseprogressioninhyperglycemicandnormoglycemicanimals |